Search

Your search keyword '"Attard G"' showing total 903 results
Start Over Author "Attard G"
903 results on '"Attard G"'

152. A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone

Author

Attard, G., primary, Montgomery, R., additional, Vaishampayan, U., additional, Gordon, M., additional, Smith, D., additional, Antonarakis, E., additional, Rudsinski, E., additional, Perabo, F., additional, Chi, K., additional, and Fizazi, K., additional

Published
2016
Full Text
View/download PDF

153. Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses

Author

Lorente, D., Omlin, A., Zafeiriou, Z., Nava-Rodrigues, D., Perez-Lopez, R., Pezaro, C., Mehra, N., Sheridan, E., Figueiredo, I., Riisnaes, R., Miranda, S., Crespo, M., Flohr, P., Mateo, J., Altavilla, A., Ferraldeschi, R., Bianchini, D., Attard, G., Tunariu, N., Bono, J. De, Lorente, D., Omlin, A., Zafeiriou, Z., Nava-Rodrigues, D., Perez-Lopez, R., Pezaro, C., Mehra, N., Sheridan, E., Figueiredo, I., Riisnaes, R., Miranda, S., Crespo, M., Flohr, P., Mateo, J., Altavilla, A., Ferraldeschi, R., Bianchini, D., Attard, G., Tunariu, N., and Bono, J. De

Abstract

Contains fulltext : 172090.pdf (Publisher’s version ) (Open Access), BACKGROUND: The urgent need for castration-resistant prostate cancer molecular characterization to guide treatment has been constrained by the disease's predilection to metastasize primarily to bone. We hypothesized that the use of clinical and imaging criteria could maximize tissue acquisition from bone marrow biopsies (BMBs). We aimed to develop a score for the selection of patients undergoing BMB. MATERIALS AND METHODS: A total of 115 BMBs were performed in 101 patients: 57 were included in a derivation set and 58 were used as the validation set. The clinical and laboratory data and prebiopsy computed tomography parameters (Hounsfield units [HUs]) were determined. A score for the prediction of biopsy positivity was developed from logistic regression analysis of the derivation set and tested in the validation set. RESULTS: Of the 115 biopsy specimens, 75 (62.5%) were positive; 35 (61.4%) in the test set and 40 (69%) in the validation set. On univariable analysis, hemoglobin (P = .019), lactate dehydrogenase (P = .003), prostate-specific antigen (P = .005), and mean HUs (P = .004) were selected. A score based on the LDH level (>/= 225 IU/L) and mean HUs (>/= 125) was developed in multivariate analysis and was associated with BMB positivity in the validation set (odds ratio, 5.1; 95% confidence interval, 1.9%-13.4%; P = .001). The area under the curve of the score was 0.79 in the test set and 0.77 in the validation set. CONCLUSION: BMB of the iliac crest is a feasible technique for obtaining tumor tissue for genomic analysis in patients with castration-resistant prostate cancer metastatic to the bone. A signature based on the mean HUs and LDH level can predict a positive yield with acceptable internal validity. Prospective studies of independent cohorts are needed to establish the external validity of the score.

Published
2016

159. 844O - Docetaxel for hormone-naïve prostate cancer: Results from long-term follow-up of metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476) and sub-group analysis by metastatic burden

Author

Clarke, N.W., Ali, A., Ingleby, F.C., Hoyle, A., Calvert, J., Attard, G., Chowdhury, S., Dearnaley, D., Douis, H., Gillessen, S., Jones, R., Malik, Z., Mason, M.D., Millman, R., Parker, C., Rush, H.L., Omlin, A.G., Sydes, M.R., Parmar, M.K.B., and James, N.D.

Published
2019
Full Text
View/download PDF

164. Increased choline uptake in androgen receptor (AR) copy number gain castration-resistant prostate cancers (CRPC)

Author

Conteduca, V., primary, Casadio, V., additional, Caroli, P., additional, Scarpi, E., additional, Lolli, C., additional, Menna, C., additional, Bianchi, E., additional, Schepisi, G., additional, Testoni, S., additional, Gurioli, G., additional, Salvi, S., additional, Amadori, D., additional, Paganelli, G., additional, Matteucci, F., additional, Attard, G., additional, and De Giorgi, U., additional

Published
2016
Full Text
View/download PDF

165. Principal results of the cancer of the ovary abiraterone trial (CORAL): A phase II study of abiraterone in patients with recurrent epithelial ovarian cancer (CRUKE/12/052)

Author

Banerjee, S., primary, Kilburn, L., additional, Bowen, R., additional, Tovey, H., additional, Hall, M., additional, Kaye, S., additional, Rustin, G., additional, Gore, M., additional, McLachlan, J., additional, Attygalle, A., additional, Tunariu, N., additional, Lima, J.P., additional, Chatfield, P., additional, Jeffs, L., additional, Folkerd, E., additional, Hills, M., additional, Perry, S., additional, Attard, G., additional, Dowsett, M., additional, and Bliss, J., additional

Published
2016
Full Text
View/download PDF

166. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

Author

UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - SSS/IREC/IMAG - Pôle d'imagerie médicale, UCL - (SLuc) Service d'urologie, UCL - (SLuc) Service de radiologie, Gillessen, S, Omlin, A, Attard, G, de Bono, J S, Efstathiou, E, Fizazi, K, Halabi, S, Nelson, P S, Sartor, O, Smith, M R, Soule, H R, Akaza, H, Beer, T M, Beltran, H, Chinnaiyan, A M, Daugaard, G, Davis, I D, De Santis, M, Drake, C G, Eeles, R A, Fanti, S, Gleave, M E, Heidenreich, A, Hussain, M, James, N D, Lecouvet, Frédéric, Logothetis, C J, Mastris, K, Nilsson, S, Oh, W K, Olmos, D, Padhani, A R, Parker, C, Rubin, M A, Schalken, J A, Scher, H I, Sella, A, Shore, N D, Small, E J, Sternberg, C N, Suzuki, H, Sweeney, C J, Tannock, I F, Tombal, Bertrand, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - SSS/IREC/IMAG - Pôle d'imagerie médicale, UCL - (SLuc) Service d'urologie, UCL - (SLuc) Service de radiologie, Gillessen, S, Omlin, A, Attard, G, de Bono, J S, Efstathiou, E, Fizazi, K, Halabi, S, Nelson, P S, Sartor, O, Smith, M R, Soule, H R, Akaza, H, Beer, T M, Beltran, H, Chinnaiyan, A M, Daugaard, G, Davis, I D, De Santis, M, Drake, C G, Eeles, R A, Fanti, S, Gleave, M E, Heidenreich, A, Hussain, M, James, N D, Lecouvet, Frédéric, Logothetis, C J, Mastris, K, Nilsson, S, Oh, W K, Olmos, D, Padhani, A R, Parker, C, Rubin, M A, Schalken, J A, Scher, H I, Sella, A, Shore, N D, Small, E J, Sternberg, C N, Suzuki, H, Sweeney, C J, Tannock, I F, and Tombal, Bertrand

Abstract

The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for the ten most important areas of controversy in advanced prostate cancer (APC) management. The successful registration of several drugs for castration-resistant prostate cancer and the recent studies of chemo-hormonal therapy in men with castration-naïve prostate cancer have led to considerable uncertainty as to the best treatment choices, sequence of treatment options and appropriate patient selection. Management recommendations based on expert opinion, and not based on a critical review of the available evidence, are presented. The various recommendations carried differing degrees of support, as reflected in the wording of the article text and in the detailed voting results recorded in supplementary Material, available at Annals of Oncology online. Detailed decisions on treatment as always will involve consideration of disease extent and location, prior treatments, host factors, patient preferences as well as logistical and economic constraints. Inclusion of men with APC in clinical trials should be encouraged.

Published
2015

167. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

Author

Gillessen, S, Omlin, A, Attard, G, de Bono, JS, Efstathiou, E, Fizazi, K, Halabi, S, Nelson, PS, Sartor, O, Smith, MR, Soule, HR, Akaza, H, Beer, TM, Beltran, H, Chinnaiyan, AM, Daugaard, G, Davis, ID, De Santis, M, Drake, CG, Eeles, RA, Fanti, S, Gleave, ME, Heidenreich, A, Hussain, M, James, ND, Lecouvet, FE, Logothetis, CJ, Mastris, K, Nilsson, S, Oh, WK, Olmos, D, Padhani, AR, Parker, C, Rubin, MA, Schalken, JA, Scher, HI, Sella, A, Shore, ND, Small, EJ, Sternberg, CN, Suzuki, H, Sweeney, CJ, Tannock, IF, Tombal, B, Gillessen, S, Omlin, A, Attard, G, de Bono, JS, Efstathiou, E, Fizazi, K, Halabi, S, Nelson, PS, Sartor, O, Smith, MR, Soule, HR, Akaza, H, Beer, TM, Beltran, H, Chinnaiyan, AM, Daugaard, G, Davis, ID, De Santis, M, Drake, CG, Eeles, RA, Fanti, S, Gleave, ME, Heidenreich, A, Hussain, M, James, ND, Lecouvet, FE, Logothetis, CJ, Mastris, K, Nilsson, S, Oh, WK, Olmos, D, Padhani, AR, Parker, C, Rubin, MA, Schalken, JA, Scher, HI, Sella, A, Shore, ND, Small, EJ, Sternberg, CN, Suzuki, H, Sweeney, CJ, Tannock, IF, and Tombal, B

Abstract

The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for the ten most important areas of controversy in advanced prostate cancer (APC) management. The successful registration of several drugs for castration-resistant prostate cancer and the recent studies of chemo-hormonal therapy in men with castration-naïve prostate cancer have led to considerable uncertainty as to the best treatment choices, sequence of treatment options and appropriate patient selection. Management recommendations based on expert opinion, and not based on a critical review of the available evidence, are presented. The various recommendations carried differing degrees of support, as reflected in the wording of the article text and in the detailed voting results recorded in supplementary Material, available at Annals of Oncology online. Detailed decisions on treatment as always will involve consideration of disease extent and location, prior treatments, host factors, patient preferences as well as logistical and economic constraints. Inclusion of men with APC in clinical trials should be encouraged.

Published
2015

168. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Author

James, ND, Sydes, MR, Clarke, NW, Mason, MD, Dearnaley, DP, Spears, MR, Ritchie, AWS, Parker, CC, Russell, JM, Attard, G, De Bono, J, Cross, W, Jones, RJ, Thalmann, G, Amos, C, Matheson, D, Millman, R, Alzouebi, M, Beesley, S, Birtle, AJ, Brock, S, Cathomas, R, Chakraborti, P, Chowdhury, S, Cook, A, Elliott, T, Gale, J, Gibbs, S, Graham, JD, Hetherington, J, Hughes, R, Laing, R, McKinna, F, McLaren, DB, O'Sullivan, JM, Parikh, O, Peedell, C, Protheroe, A, Robinson, AJ, Srihari, N, Srinivasan, R, Staffurth, J, Sundar, S, Tolan, S, Tsang, D, Wagstaff, J, Parmar, MKB, James, ND, Sydes, MR, Clarke, NW, Mason, MD, Dearnaley, DP, Spears, MR, Ritchie, AWS, Parker, CC, Russell, JM, Attard, G, De Bono, J, Cross, W, Jones, RJ, Thalmann, G, Amos, C, Matheson, D, Millman, R, Alzouebi, M, Beesley, S, Birtle, AJ, Brock, S, Cathomas, R, Chakraborti, P, Chowdhury, S, Cook, A, Elliott, T, Gale, J, Gibbs, S, Graham, JD, Hetherington, J, Hughes, R, Laing, R, McKinna, F, McLaren, DB, O'Sullivan, JM, Parikh, O, Peedell, C, Protheroe, A, Robinson, AJ, Srihari, N, Srinivasan, R, Staffurth, J, Sundar, S, Tolan, S, Tsang, D, Wagstaff, J, and Parmar, MKB

Published
2015

176. Microbial synthesis of core/shell gold/palladium nanoparticles for applications in green chemistry

Author

Deplanche, K., Merroun, M. L., Casadesus, M., Tran, D. T., Mikheenko, I. P., Bennett, J. A., Wood, J., Jones, I. P., Attard, G. A., Selenska-Pobell, S., and Macaskie, L. E.

Subjects
catalysis, Escherichia coli, bimetallic catalysts, core/shell, gold, bioreduction, palladium
Abstract

We report a novel biochemical method based on the sacrificial hydrogen strategy to synthesise bimetallic Au/Pd nanoparticles (NPs) with a core/shell configuration. The ability of E. coli cells supplied with H2 as electron donor to rapidly precipitate Pd(II) ions from solution is used to promote the reduction of soluble Au(III). Pre-coating cells with Pd(0) (bioPd) dramatically accelerated Au(III) reduction, with the Au(III) reduction rate being dependent upon the initial Pd loading by mass on the cells. Following Au(III) addition, the bioPd/Au(III) mixture rapidly turned purple indicating the formation of colloidal gold. Mapping of bio-NPs by energy dispersive X-ray microanalysis (EDX) suggested Au-dense core regions and peripheral Pd but only Au was detected by X-ray diffraction analysis. However surface analysis of cleaned NPs by cyclic voltammetry (CV) revealed largely Pd surface sites, suggesting, since XRD shows no crystalline Pd component, that layers of Pd atoms surround Au NPs. Characterisation of the bimetallic particles using X-ray absorption spectroscopy (XANES and EXAFS) confirmed the existence of Au-rich core and Pd-rich shell type bimetallic biogenic NPs. These showed comparable catalytic activity to chemical counterparts with respect to the oxidation of benzyl alcohol, in air, and at a low temperature (90 oC).

Published
2012

177. 2577 The correlation between circulating cell-free AR and CYP17A1 copy number variations and tumor burden estimated by 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone

Author

Conteduca, V., primary, Salvi, S., additional, Caroli, P., additional, Scarpi, E., additional, Lolli, C., additional, Burgio, S.L., additional, Menna, C., additional, Schepisi, G., additional, Bianchi, E., additional, Gurioli, G., additional, Paganelli, G., additional, Casadio, V., additional, Matteucci, F., additional, Attard, G., additional, and De Giorgi, U., additional

Published
2015
Full Text
View/download PDF

178. 2558 Impact of PTEN protein loss on response to docetaxel and overall survival (OS) in metastatic castration resistant prostate cancer (mCRPC) patients

Author

Rescigno, P., primary, Lorente, D., additional, Bianchini, D., additional, Kolinsky, M., additional, Zafeiriou, Z., additional, Ferraldeschi, R., additional, Mateo, J., additional, Recine, F., additional, Jayaram, A., additional, Nava Rodrigues, D., additional, Riisnaes, R., additional, Miranda, S., additional, Figueiredo, I., additional, Crespo, M., additional, Mehra, N., additional, Perez-Lopez, R., additional, Tunariu, N., additional, Reid, A., additional, Attard, G., additional, and De Bono, J., additional

Published
2015
Full Text
View/download PDF

179. 2537 Preliminary findings from PLATO: A two-period, phase 4, randomized, double-blind, placebo-controlled study of continued enzalutamide treatment beyond progression in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC)

Author

Attard, G., primary, Gurney, H., additional, Loriot, Y., additional, Borre, M., additional, Andresen, C., additional, Wu, K., additional, Taylor, C., additional, Amelsberg, A., additional, and Taplin, M.E., additional

Published
2015
Full Text
View/download PDF

181. Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone

Author

Salvi, S, primary, Casadio, V, additional, Conteduca, V, additional, Burgio, S L, additional, Menna, C, additional, Bianchi, E, additional, Rossi, L, additional, Carretta, E, additional, Masini, C, additional, Amadori, D, additional, Calistri, D, additional, Attard, G, additional, and De Giorgi, U, additional

Published
2015
Full Text
View/download PDF

182. Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents

Author

Crespo, M, primary, van Dalum, G, additional, Ferraldeschi, R, additional, Zafeiriou, Z, additional, Sideris, S, additional, Lorente, D, additional, Bianchini, D, additional, Rodrigues, D N, additional, Riisnaes, R, additional, Miranda, S, additional, Figueiredo, I, additional, Flohr, P, additional, Nowakowska, K, additional, de Bono, J S, additional, Terstappen, L W M M, additional, and Attard, G, additional

Published
2015
Full Text
View/download PDF

183. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer

Author

Reid, AHM, Attard, G, Ambroisine, L, Fisher, G, Kovacs, G, Brewer, D, Clark, J, Flohr, P, Edwards, S, Berney, DM, Foster, CS, Fletcher, A, Gerald, WL, Møller, H, Reuter, VE, Scardino, PT, Cuzick, J, de Bono, JS, Cooper, CS, and Transatlantic Prostate Group

Abstract

BACKGROUND: The discovery of ERG/ETV1 gene rearrangements and PTEN gene loss warrants investigation in a mechanism-based prognostic classification of prostate cancer (PCa). The study objective was to evaluate the potential clinical significance and natural history of different disease categories by combining ERG/ETV1 gene rearrangements and PTEN gene loss status. METHODS: We utilised fluorescence in situ hybridisation (FISH) assays to detect PTEN gene loss and ERG/ETV1 gene rearrangements in 308 conservatively managed PCa patients with survival outcome data. RESULTS: ERG/ETV1 gene rearrangements alone and PTEN gene loss alone both failed to show a link to survival in multivariate analyses. However, there was a strong interaction between ERG/ETV1 gene rearrangements and PTEN gene loss (P

Published
2010

184. Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial

Author

Attard, G, Sydes, MR, Mason, MD, Clarke, NW, Aebersold, D, de Bono, JS, Dearnaley, DP, Parker, CC, Ritchie, AWS, Russell, JM, Thalmann, G, Cassoly, E, Millman, R, Matheson, D, Schiavone, F, Spears, MR, Parmar, MKB, James, ND, Attard, G, Sydes, MR, Mason, MD, Clarke, NW, Aebersold, D, de Bono, JS, Dearnaley, DP, Parker, CC, Ritchie, AWS, Russell, JM, Thalmann, G, Cassoly, E, Millman, R, Matheson, D, Schiavone, F, Spears, MR, Parmar, MKB, and James, ND

Abstract

There are compelling reasons to study the addition of both enzalutamide and abiraterone, in combination, to standard-of-care for hormone-naïve prostate cancer. Through a protocol amendment, this will be assessed in the STAMPEDE trial, with overall survival as primary outcome measure. © 2014 European Association of Urology.

Published
2014

186. Food, rural, agricultural and fisheries policies in Turkey

Author

Attard, G., Meli, A., Adamolle, Cécile, Allaya, M. (ed.), and University of Malta [Malta]

Subjects
SECTEUR AGRICOLE, AGRICULTURAL SECTOR, AGRICULTURAL POLICIES, [SDV.SA.AEP] Life Sciences [q-bio]/Agricultural sciences/Agriculture, economy and politics, STATISTICAL DATA, [SDV.SA.AEP]Life Sciences [q-bio]/Agricultural sciences/Agriculture, economy and politics, PRODUCTION AGRICOLE, INTERNATIONAL TRADE, RURAL DEVELOPMENT, POLITIQUE AGRICOLE, DONNEE STATISTIQUE, [SHS]Humanities and Social Sciences, TURKEY, COMMERCE INTERNATIONAL, AGRICULTURAL TRADE, [SHS] Humanities and Social Sciences, TURQUIE, DEVELOPPEMENT RURAL, ComputingMilieux_MISCELLANEOUS, COMMERCE AGRICOLE, ECONOMIC SITUATION, AGRICULTURAL PRODUCTION, SITUATION ECONOMIQUE
Abstract

International audience

Published
2008

187. 72 - Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status

Author

Jayaram, A., Nowakowska, K., Mateo, J., Hernandez, T., Kumar, S., Fulton, B., Nava Rodrigues, D., Riisnaes, R., Zukiwski, A., Proniuk, S., Bexon, A.S., Bisaha, J., Bianchini, D., Zafeiriou, Z., Lopez, R.P., Tunariu, N., Pacey, S., Jones, R., de Bono, J. Sebastian, and Attard, G.

Published
2017
Full Text
View/download PDF

188. 1674P - Exploratory study of CK-M30 and pHH3 expression in Circulating Tumor Cells (CTCs) as biomarkers of docetaxel (DOC) efficacy in metastatic castration resistant prostate cancer (mCRPC)

Author

Nombela Blanco, P., Lozano Mejorada, R., Lorente Estelles, D., Reid, A., Romero Laorden, N., Attard, G., Cendón Flórez, Y., Mateo, J., Sandhu, S., Massard, C., Montesa, A., Flohr, P., Sáez, M.I., Pacheco, M.I., Castro Marcos, E., de Bono, J., and Olmos Hidalgo, D.

Published
2017
Full Text
View/download PDF

190. 800P - Phase II study of prednisone-dexamethasone switch in metastatic castration resistant prostate cancer (mCRPC) patients treated with abiraterone and prednisone (AA+P)

Author

Lozano Mejorada, R., Romero Laorden, N., Jayaram, A., López, F., Sáez, M.I., Villatoro, R., Montesa, A., Moreno, I., Ruiz Vico, M., García Ferrón, M., Rogado, J., Cendón Flórez, Y., Nombela Blanco, P., Rivera, L., Grau, G., Cruz Hernandez, J.J., Lorente Estelles, D., Attard, G., Castro Marcos, E., and Olmos Hidalgo, D.

Published
2017
Full Text
View/download PDF

193. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone

Author

Lorente, D, primary, Omlin, A, additional, Ferraldeschi, R, additional, Pezaro, C, additional, Perez, R, additional, Mateo, J, additional, Altavilla, A, additional, Zafeirou, Z, additional, Tunariu, N, additional, Parker, C, additional, Dearnaley, D, additional, Gillessen, S, additional, de Bono, J, additional, and Attard, G, additional

Published
2014
Full Text
View/download PDF

194. CTCtrap – Circulating Tumor Cells TheRapeutic APheresis: a novel biotechnology enabling personalized therapy for all cancer patients

Author

Neubauer, H, primary, Kasprowicz, N, additional, Rack, B, additional, Vizler, C, additional, Scholz, M, additional, Ventola, A, additional, van Rijn, C, additional, Aaspollu, A, additional, Zamarchi, R, additional, Attard, G, additional, Farrace, F, additional, Terstappen, L, additional, and Fehm, T, additional

Published
2014
Full Text
View/download PDF

195. Impact of Node Status and Radiotherapy on Failure-Free Survival in Patients With Newly–Diagnosed Non-Metastatic Prostate Cancer: Data From >690 Patients in the Control Arm of the STAMPEDE Trial

Author

James, N.D., primary, Spears, M.R., additional, Clarke, N.W., additional, Sydes, M.R., additional, Parker, C.C., additional, Dearnaley, D.P., additional, Russell, J.M., additional, Ritchie, A.W.S., additional, Thalmann, G., additional, De Bono, J.S., additional, Attard, G., additional, Amos, C., additional, Parmar, M.K., additional, and Mason, M.D., additional

Published
2014
Full Text
View/download PDF

196. Sequencing of Docetaxel (D) and Abiraterone Acetate (Aa) for Metastatic Castration-Resistant Prostate Cancer (Mcrpc)

Author

Zafeiriou, Z., primary, Ferraldeschi, R., additional, Omlin, A., additional, Pezaro, C., additional, Mukherji, D., additional, Lorente, D., additional, Altavilla, A., additional, Sideris, S., additional, Rescigno, P., additional, Mateo, J., additional, Bianchini, D., additional, Smith, A., additional, Lopez, R. Perez, additional, Mehra, N., additional, Ravi, P., additional, Grist, E., additional, Tunariu, N., additional, Attard, G., additional, and de Bono, J.S., additional

Published
2014
Full Text
View/download PDF

197. Prognostic Relevance of Imaging Bone Metastases By Whole Body Diffusion-Weighted Magnetic Resonance Imaging (Wbdwi) in Metastatic Castration-Resistant Prostate Cancer (Mcrpc)

Author

Lopez, R. Perez, primary, Lorente, D., additional, Mateo, J., additional, Blackledge, M.D., additional, Sideris, S., additional, Zafeiriou, Z., additional, Smith, A., additional, Ferraldeschi, R., additional, Rescigno, P., additional, Rata, M., additional, Naumann, U., additional, Collins, D.J., additional, Attard, G., additional, Leach, M.O., additional, Koh, D., additional, de Bono, J.S., additional, and Tunariu, N., additional

Published
2014
Full Text
View/download PDF

198. Serial Next Generation Sequencing of Cfdna to Monitor Phase I Targeted Drug Administration

Author

Frenel, J., primary, Carreira, S., additional, Goodall, J., additional, Roda-Perez, D., additional, Smith, A., additional, Mateo, J., additional, Ong, M., additional, Gasi-Tandefelt, D., additional, Yap, T.A., additional, Attard, G., additional, Nava-Rodrigues, D., additional, Molife, L.R., additional, Kaye, S.B., additional, Banerji, U., additional, and de Bono, J.S., additional

Published
2014
Full Text
View/download PDF

199. Impact of Node Status and Radiotherapy on Failure-Free Survival in Patients with Newly Diagnosed Non-Metastatic Prostate Cancer: Data from >690 Patients in the Control Arm of the Stampede Trial

Author

James, N., primary, Spears, M., additional, Clarke, N.W., additional, Sydes, M., additional, Parker, C., additional, Dearnaley, D., additional, Russell, J.M., additional, Ritchie, A., additional, Thalmann, G., additional, de Bono, J.S., additional, Attard, G., additional, Amos, C., additional, Parmar, M.K., additional, and Mason, M., additional

Published
2014
Full Text
View/download PDF

200. Antitumour Activity of the Parp Inhibitor Olaparib in Unselected Sporadic Castration-Resistant Prostate Cancer (Crpc) in the Toparp Trial

Author

Mateo, J., primary, Hall, E., additional, Sandhu, S., additional, Omlin, A.G., additional, Miranda, S., additional, Carreira, S., additional, Goodall, J., additional, Gillman, A., additional, Mossop, H., additional, Ralph, C., additional, Zafeiriou, Z., additional, Perez Lopez, R., additional, Tunariu, N., additional, Ferraldeschi, R., additional, Nava Rodrigues, D., additional, Kunju, L.P., additional, Robinson, D., additional, Attard, G., additional, Chinnaiyan, A., additional, and de Bono, J.S., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results